Core Insights - The home health aide profession employs nearly 4 million individuals as of 2024, but the median pay is only $34,900, reflecting a broader trend of low wages in many common jobs in America [1][2] - Among the 20 most prevalent jobs, only two offer six-figure salaries, and only five exceed $50,000 annually, indicating a significant disparity between job availability and compensation [2] - Common jobs, such as retail sales and home health aides, are abundant, but they often come with low pay and little job security, making it challenging for workers to achieve financial stability [5][6] Job Market Overview - The service economy dictates job availability, with positions like cashiers and home health aides being essential yet low-paying [2] - The number of retail sales jobs is substantial, with 3.8 million positions available, suggesting accessibility in various markets [2] - However, economic downturns, such as the Great Recession of 2008, can make even these common jobs harder to find, challenging the assumption of job security [3] Compensation and Job Security - The majority of the most common jobs do not require a bachelor's degree, with general and operational managers earning a median income of $102,950 and registered nurses earning $93,600 [5] - Fast food and counter jobs, which require no formal education, average $30,480 annually, highlighting the low compensation in these roles [6] - Workers in low-paying jobs often face the risk of being easily replaced, contributing to a lack of job security [7] Economic Implications - Earning barely $30,000 a year in low-wage jobs makes it difficult for individuals to support a family, necessitating dual incomes to achieve middle-class status [8][9]

Financial Performance & Guidance - Aveanna's 2025 revenue guidance is in the range of $2425 million to $2445 million[14, 63] - The adjusted EBITDA guidance for 2025 is $318 million to $322 million[14, 63] - The company projects 2026 revenue in the range of $2540 million to $2560 million[70] - The adjusted EBITDA guidance for 2026 is $318 million to $322 million[70] - Q3 2025 revenue was $621.9 million, a 22.2% increase year-over-year[53] - Q3 2025 adjusted EBITDA was $80.1 million, a 67.5% increase year-over-year[53] Segment Performance - Private Duty Services (PDS) revenue for 2025 is $1947 million[28] - Home Health & Hospice (HHH) revenue for 2025 is $239 million[34] - Medical Solutions (MS) revenue for 2025 is $175 million[43] Key Operating Statistics - Aveanna has 366 locations across 38 states[14] - The company employs approximately 29,000 caregivers[14] - Aveanna delivers approximately 45 million homecare hours annually[14]

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HALIFAX, Nova Scotia, Dec. 12, 2025 (GLOBE NEWSWIRE) -- NOVA LEAP HEALTH CORP. (TSXV: NLH) (“Nova Leap” or “the Company”), a growing home health care organization, announces that the Company has issued stock options. The Company has granted 950,000 incentive stock options to directors, officers and senior employees of the Company. The stock options are exercisable for a period of 10 years at an exercise price of CAD$0. ...

Group 1 - Israel's stock market has outperformed the U.S. market since October 7, 2023, with significant gains in U.S.-traded companies such as Teva Pharmaceutical, Elbit Systems, and Tower Semiconductor [5] - BrightSpring Health Services, a recent IPO, has pulled back from record highs but remains in a buy zone, making it a stock to watch according to Investor's Business Daily [6][10] - BrightSpring Health Services has seen its relative strength rating jump to 81, indicating strong performance among stocks [10] Group 2 - The health care sector is attracting attention, with BrightSpring Health leading in potential triple-digit profit growth [10] - The market is currently volatile, with Russell 2000 showing significant movement, and key stocks like AbbVie and BrightSpring being highlighted for their performance [6]

Core Insights - Extendicare Inc. announced the acquisition of CBI Home Health for a cash purchase price of $570 million, which will enhance its service offerings and strengthen its market position in home health care [2][3][11] - The acquisition is expected to generate significant synergies and improve financial metrics, including a projected 20% accretion in AFFO per share and 15% in earnings per share [9][11] Acquisition Details - The acquisition will be funded through a combination of a $264.5 million upsizing to Extendicare's existing credit facility and a $200 million bought deal private placement equity offering [5][15][16] - CBI Home Health delivered over 10 million hours of care annually across seven provinces, with a revenue of approximately $477.9 million and an Adjusted EBITDA of $61.9 million for the twelve months ended July 31, 2025 [10][11] Financial Metrics - The acquisition price represents an estimated purchase price multiple of 9.4x CBI Home Health's Adjusted EBITDA, which could improve to approximately 8.4x after accounting for expected synergies of about $7.4 million [11][12] - Extendicare's pro forma total debt to Adjusted EBITDA ratio is projected to be 3.3x as of September 30, 2025, post-acquisition [8][15] Strategic Rationale - The acquisition aligns with Extendicare's growth strategy by enhancing its capabilities in home health care and expanding its geographic footprint, particularly in Western Canada [6][9] - The combination of ParaMed and CBI Home Health is expected to improve access to community-based care and leverage technology for better customer experience and cost efficiencies [6][9] Offering Details - Extendicare plans to issue 10.64 million common shares at a price of $18.80 per share, aiming for gross proceeds of approximately $200 million from the private placement [5][17] - The closing of the offering is anticipated around December 3, 2025, subject to regulatory approvals [17]

Acquisition Overview - Extendicare is acquiring CBI Home Health for $570 million[37, 94] - The acquisition is expected to be accretive to Extendicare's AFFO per share by 15% and earnings per share by 9%[34] - Post-synergies, the accretion is expected to increase to 20% for AFFO per share and 15% for earnings per share[34] - CBI Home Health's revenue for the twelve months ended July 31, 2025, was $478 million, with adjusted EBITDA of $61.9 million[34, 35, 87] - The purchase price represents 9.4x EV/Adjusted EBITDA pre-synergies and 8.4x post-synergies[94] Financing and Leverage - The acquisition will be funded through a combination of $26 million cash on hand, $200 million equity private placement, $205 million term loan, and $154 million revolver[37, 98] - Pro forma total debt to Adjusted EBITDA is expected to be 3.3x at transaction close[99] Extendicare's Business Segments - ParaMed, Extendicare's home health care segment, delivers over 13.5 million hours of home health care annually across 3 provinces[28, 40] - Extendicare operates 59 fully owned long-term care homes and manages 40 homes, representing approximately 7% of the Canadian market and 13% of the Ontario market[28] - Extendicare's managed services segment serves approximately 152,000 third-party and JV beds[42, 71] Market and Growth - The number of Canadians aged 85+ is projected to double by 2036 and triple by 2051[48] - ParaMed's care volumes grew by more than 10% in 2024 vs 2023 and increased 13% YTD Q3 2025 vs YTD Q3 2024[51] - Extendicare has a joint venture with Axium Infrastructure to redevelop LTC homes, with six homes under construction and 1,408 new beds replacing 1,097 Class C beds[77, 78]

Core Viewpoint - Nova Leap Health Corp. reported record financial results for Q3 2025, achieving significant growth in revenues and Adjusted EBITDA, reflecting strong operational performance and strategic execution [2][4][7]. Financial Performance - Q3 2025 revenues reached $8,264,326, marking a 3% increase from Q2 2025 and a 29% increase from Q3 2024 [2]. - Adjusted EBITDA for Q3 2025 was $670,706, up 16.1% from Q2 2025 and 76.9% from Q3 2024 [4]. - The gross profit margin was 39.6% in Q3 2025, compared to 40.2% in Q2 2025 and 38.0% in Q3 2024 [10]. Record Achievements - The company set nine financial records in Q3 2025, including consolidated revenues, gross margin, and Adjusted EBITDA [5][7]. - Canadian and U.S. operating segments also achieved record revenues, gross margins, and Adjusted EBITDA [5]. Operational Insights - The company has established a new performance benchmark with Adjusted EBITDA averaging over $400,000 quarterly from Q2 2023 to Q1 2025, now reset to higher levels [8]. - The company generated income from operating activities of $418,553 in Q3 2025, an increase from previous quarters [10]. Financial Position - As of September 30, 2025, the company had available cash of $1,571,716 and access to an unutilized revolving credit facility of $1,077,509 [10]. - Total demand loans and promissory notes outstanding were $2,300,800, resulting in a leverage ratio of 1.18 times to trailing twelve-month Adjusted EBITDA [10]. Strategic Focus - The company emphasizes disciplined growth, profitability, and long-term value creation, supported by a strong balance sheet and positive operating cash flow [9][10].

Financial Data and Key Metrics Changes - Consolidated net revenue totaled $263.6 million, an increase of $10 million or 3.9% year over year [17] - Consolidated adjusted EBITDA was $27 million, reflecting a sequential increase of $0.1 million or 0.4% and a year-over-year increase of $2.5 million or 10.2% [18] - Net debt to adjusted EBITDA leverage ratio improved to 3.9 times, down from 5.4 times in Q4 2023 [15][26] Business Line Data and Key Metrics Changes - Home Health total admissions increased by 3.6% year over year, with a census increase of 3.7% [7] - Hospice segment revenue reached $63.1 million, reflecting a year-over-year growth of 20% [22] - Home health adjusted EBITDA totaled $33.9 million, a decrease of 7.1% year over year [20] Market Data and Key Metrics Changes - Fee-for-Service Medicare census stabilized with a decline of only 1.4% year over year, compared to a 14.1% decline in Q3 2024 [8] - Non-Medicare admissions increased by 10.4%, contributing to a 2.8% increase in non-Medicare revenue per visit year over year [8] Company Strategy and Development Direction - The company is focused on mitigating pricing headwinds from the CMS 2026 Home Health Final Rule through various strategies [29] - The de novo strategy is positively impacting total growth, with plans to open a total of 10 de novos in 2025 [11] - The company aims to improve operational efficiency and reduce costs to strategically invest in people and technology [12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's positioning within the industry, citing experienced leaders and innovative technology [13] - The company anticipates continued growth momentum into Q4 and has updated full-year guidance for revenue and adjusted EBITDA [27][28] - Management highlighted the importance of maintaining staffing productivity to offset wage inflation [44] Other Important Information - The company has successfully reduced overall bank debt by $15.5 million during the quarter, with a total reduction of $100 million since Q4 2023 [26] - Home office expenses improved to 9.1% of revenues, down from 9.9% in the prior quarter, reflecting effective cost management initiatives [25] Q&A Session Summary Question: Can you provide some color on the rate increase from the new payer innovation contract in November? - Management indicated that they cannot disclose specific updates but mentioned that more regional agreements will be coming up for renewal in the next year [33] Question: Can you provide details on the G&A expense reduction? - Management noted that the reduction came from headcount adjustments and efficiencies gained by insourcing capabilities, estimating that $1 million-$1.5 million of the improvement is durable [34] Question: What seasonal factors drive hospice performance at the end of the year? - Management acknowledged that holiday times can be unpredictable, with patients often delaying decisions until after the holidays [38] Question: How long is the typical recontracting cycle for payer innovation contracts? - Management stated that most contracts are typically three years, with some being two years [40] Question: How is the company managing labor costs and wage inflation? - Management reported an uptick in the applicant pool for nursing and therapy, with wage inflation expected to normalize around 3% [44]

Core Insights - The Pennant Group, Inc. reported a GAAP diluted earnings per share of $0.17 and an adjusted diluted earnings per share of $0.30 for Q3 2025, reflecting strong operational performance across its segments [1][4][6]. Financial Performance - Total revenue for Q3 2025 was $229.0 million, a 26.8% increase from the prior year [4]. - Net income for Q3 2025 was $6.1 million, a slight decrease of 2.0% compared to the previous year [4]. - Adjusted net income for Q3 2025 was $10.4 million, up 27.6% year-over-year [4]. - Consolidated Adjusted EBITDAR for Q3 2025 was $29.3 million, a 12.8% increase from the prior year [4]. - Consolidated Adjusted EBITDA for Q3 2025 was $17.3 million, reflecting a 14.5% increase year-over-year [4]. Segment Performance - Home Health and Hospice Services segment revenue was $173.6 million, a 27.9% increase from the prior year [4]. - Senior Living Services segment revenue was $55.5 million, up 23.2% year-over-year [4]. - Total home health admissions increased by 36.2% to 20,426 in Q3 2025 [4]. - Hospice average daily census rose by 17.4% to 4,044 [4]. - Senior Living average occupancy increased by 180 basis points to 80.9% [4]. Acquisition and Expansion - The company completed the acquisition of 54 home health, hospice, and home care operations from UnitedHealth Group and Amedisys on October 1, 2025, marking the largest transaction in its history [5]. - This acquisition is expected to enhance the company's operational capabilities and expand its market presence in the Southeast [5]. Guidance and Expectations - The company updated its 2025 annual guidance, projecting total revenue between $911.4 million and $948.6 million [6]. - Full-year adjusted earnings per diluted share is anticipated to be between $1.14 and $1.18, representing a growth of 23.4% from 2024 [7]. - The guidance reflects strong operational performance and the impact of the recent acquisition [8].

Core Insights - The announcement of The Top 50 Women Chief Growth Officers for 2025 highlights the growing importance of the Chief Growth Officer role in shaping business strategy and driving sustainable growth [1][5] Group 1: Recognition of Leaders - Jasmin Valdez, Chief Growth Officer of ProHealth Home Care, is recognized for her extensive experience in healthcare and her role in improving market position and managing marketing activities [2] - Amy Katz, Chief Growth Officer at PACE Southeast Michigan, is acknowledged for her leadership in business development and program expansion, enhancing community-based care for seniors [3] - Amanda Custodio, Chief Growth Officer of BMO Wealth Management, is celebrated for providing strategic direction for growth initiatives across various financial services [4] Group 2: Broader Impact - The initiative aims to celebrate the accomplishments of women leaders in executive roles, inspiring others to pursue leadership positions [5][7] - Women We Admire circulates content to over 70,000 individuals and businesses, emphasizing the recognition of exceptional women across various fields [7]